Ruxolitinib cream for pyoderma gangrenosum ulcers
Part of Injuries & trauma, Skin clinical trials.
This study tests a cream called ruxolitinib for people with pyoderma gangrenosum, a condition that causes painful skin ulcers. The cream is applied directly to the ulcer, and the study aims to see if it helps heal the wounds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with pyoderma gangrenosum (a rare skin condition causing painful ulcers), and you must have at least one ulcer that is 10 cm² or smaller (about the size of a large coin).
- You must not be pregnant or breastfeeding, and if you are of childbearing age, you must agree to use reliable birth control during the study and for 1 week after the last dose.
- You must not have had cancer (other than certain easily treated skin cancers) in the past 5 years.
- You must not have an active, untreated infection (like tuberculosis) or have a history of serious infections that could make the study unsafe.
- You must not have had a stroke, heart attack, or heart stent placement in the last 6 months.
- You must not have used a JAK inhibitor (such as ruxolitinib, tofacitinib, upadacitinib, filgotinib) in the past.
- You must be willing to travel to Portland, Oregon for study visits, or if you live more than 30 miles away, you must be able to do video visits and have internet access.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether guselkumab (Tremfya) can help heal painful ulcers from Pyoderma Gangrenosum (PG). Participants must already be taking steroid medication and have a PG ulcer that is at least 4 cm².
This trial tests an injection called SHR-1139 for people with pyoderma gangrenosum (a rare skin condition that causes painful ulcers). If you have at least one ulcer that is 5 cm² or larger and your PARACELSUS score is at least 10, you may be able to join.
This study tests an investigational drug called SHR-1139 for adult patients with ulcerative pyoderma gangrenosum (a type of painful skin ulcer). The goal is to see if the drug is safe and helps heal the ulcers.
This study tests whether the drug bimekizumab can help heal ulcers caused by a rare skin condition called pyoderma gangrenosum (PG). If you have PG and are already taking prednisone, this trial may offer a new treatment option.
This trial tests whether the drug spesolimab can help people with a skin condition called pyoderma gangrenosum, which causes painful ulcers. It's for adults who have at least one active ulcer that's at least 2 inches across and needs treatment.
This trial tests a cream called ruxolitinib for people with dermatomyositis whose skin symptoms haven't improved with standard treatments. It aims to see if this cream can reduce rash and activity when added to your current medications.
Hear when a new Pyoderma Gangrenosum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.